Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan C Gilbert

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
BMJ (Clinical Research Ed.)|October 20, 2011
Changing face of HPV related cancer in the UKAndrew G Schache, Richard Simcock, Duncan C Gilbert, et al.
Nature Medicine|October 6, 2022
Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global accessIan Hirsch, Daniel A Goldstein, Ian F Tannock, et al.
British Journal of Cancer|June 23, 2017
No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapyAlexandra K Walker, Christiana Kartsonaki, Elena Collantes, et al.
British Journal of Cancer|January 12, 2018
No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapyAlexandra K Walker, Christiana Kartsonaki, Elena Collantes, et al.
The Journal of Pathology. Clinical Research|October 18, 2021
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirationsTim H Ward, Duncan C Gilbert, George Higginbotham, et al.
Nuclear Medicine Communications|June 25, 2016
Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancerAlexandra R Teagle, Duncan C Gilbert, John R Jones, et al.
BJU International|July 13, 2006
Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapyDuncan C Gilbert, Andrew R Norman, Judith Nicholl, et al.
BMJ Oncology|January 31, 2025
Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid reviewHannah Louise Bromley, Mohini Varughese, Duncan C Gilbert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2013
p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapyDuncan C Gilbert, Anthony Williams, Kimberley Allan, et al.
Molecular Cancer Therapeutics|December 20, 2014
Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecanCornelia Meisenberg, Duncan C Gilbert, Anthony Chalmers, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
BMJ (Clinical Research Ed.)|October 20, 2011
Changing face of HPV related cancer in the UKAndrew G Schache, Richard Simcock, Duncan C Gilbert, et al.
Nature Medicine|October 6, 2022
Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global accessIan Hirsch, Daniel A Goldstein, Ian F Tannock, et al.
British Journal of Cancer|June 23, 2017
No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapyAlexandra K Walker, Christiana Kartsonaki, Elena Collantes, et al.
British Journal of Cancer|January 12, 2018
No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapyAlexandra K Walker, Christiana Kartsonaki, Elena Collantes, et al.
The Journal of Pathology. Clinical Research|October 18, 2021
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirationsTim H Ward, Duncan C Gilbert, George Higginbotham, et al.
Nuclear Medicine Communications|June 25, 2016
Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancerAlexandra R Teagle, Duncan C Gilbert, John R Jones, et al.
BJU International|July 13, 2006
Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapyDuncan C Gilbert, Andrew R Norman, Judith Nicholl, et al.
BMJ Oncology|January 31, 2025
Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid reviewHannah Louise Bromley, Mohini Varughese, Duncan C Gilbert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2013
p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapyDuncan C Gilbert, Anthony Williams, Kimberley Allan, et al.
Molecular Cancer Therapeutics|December 20, 2014
Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecanCornelia Meisenberg, Duncan C Gilbert, Anthony Chalmers, et al.
Pageof 6